Company intelligence / Profile preview

Arsenal Biosciences, Inc.

South San Francisco, California, United Statesarsenalbio.com ↗

Ownership: Private
Employees: ~500
Development stage: Phase 1

Overview

Currently conducting Phase 1/2 clinical trials for AB-2100 in clear-cell renal cell carcinoma (first patient dosed April 2024). Previously had AB-1015 in Phase 1 for ovarian cancer but appears to have pivoted away from this asset. The company is advancing multiple programs targeting solid tumors.

Therapeutic areas: Oncology
Modalities: CAR T-cell therapiesprogrammable cell therapies
Industry: Biotech

Drug pipeline

7 assets

AB-2100

6 more assets in the full pipeline.

Request access →

Partnerships

Bristol Myers SquibbGenentech (Roche Group)

Beyond the preview

Go deeper on Arsenal Biosciences, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Arsenal Biosciences, Inc..

Explore the full profile